Aryl isonitriles as a new class of antimicrobial compounds
The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.
1. A method for inhibiting MRSA comprising contacting MRSA with an isonitrile compound having the structure:
wherein R is a hydrogen, an alkyl, a cycloalkyl, a heteroalkyl, or an aryl group;
n is an integer from 0 to 4;
X is hydrogen, a C1 to C3 alkyl group, a halogen, alkyloxy, trihalomethyl, or a nitro group;
W, Y, and Z are each independently —CH— or N with one and only one of W, Y, or Z is N; and
pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein R is hydrogen and n is 0.
3. The method of claim 1 , wherein the amount the isonitrile compound is from about 50 μM to about 100 μM.
4. The method of claim 1 , wherein the strain of MRSA is NRS1, NRS72, NRS119, NRS382, NRS383, NRS384, NRS385, NRS386, VRS2, or combinations thereof.
5. A method for treating a patient having a MRSA infection comprising administering to the patient a therapeutically effective amount of an isonitrile compound having the structure:
wherein R is a hydrogen, an alkyl, a cycloalkyl, a heteroalkyl, or an aryl group;
n is an integer from 0 to 4;
X is hydrogen, a C1 to C3 alkyl group, a halogen, alkyloxy, trihalomethyl, or a nitro group;
W, Y, and Z are each independently —CH— or N with one and only one of W, Y, or Z is N; and
pharmaceutically acceptable salts thereof.
6. The method of claim 5 , wherein R is hydrogen and n is 0.
7. The method of claim 5 , wherein the strain of MRSA is NRS1, NRS72, NRS119, NRS382, NRS383, NRS384, NRS385, NRS386, VRS2 or combinations thereof.
8. The method of claim 6 , wherein the isonitrile compound is administered with a second antibacterial compound.